Originally published by our sister publication Pain Medicine News
Data from a new study published in the Journal of Clinical Investigation offer evidence about a reduction in neuropathic pain when the kynurenine metabolic pathway (KYNPATH) is pharmaceutically blocked in mice.
Researchers induced peripheral nerve injury and related neuropathic pain in mice using the spared nerve injury model (J Clin Invest 2022;132[23]:e153805). Mice were pharmacologically treated with the enzyme inhibitors